Bayer Innovation Procurement Expands Use of Scientist.com’s AI-Powered Platform for Global R&D Procurement Orchestration
16.6.2025 14:55:00 EEST | Business Wire | Press release
Bayer AG Innovation Procurement and Scientist.com have signed a multi-year extension that elevates Scientist.com to Bayer’s preferred global channel for sourcing external R&D services.
A Journey from Tactical to Strategic Partnership
The alliance began in 2015, when Bayer adopted Scientist.com’s digital marketplace to streamline and control long-tail spend in preclinical research. Over the years, this relationship has deepened and expanded, reflecting Bayer’s broader shift toward externalizing more of its R&D activities as part of its innovation strategies. What started as a tactical procurement tool has now become Bayer’s preferred global channel for sourcing a wide spectrum of external R&D services.
Comprehensive R&D Outsourcing Capabilities
With the expansion, Scientist.com’s platform will support Bayer across the entire R&D value chain, including:
- Strategic preclinical supplier management, with guided buying, rate-card compliance, and performance tracking.
- Clinical development services, offering unified workflows for study execution, biomarker analysis, and central laboratory capabilities.
- Real-world evidence, data analytics, health economics, and market access solutions, providing rapid access to top-tier data partners.
- Crop science research, including specialized agriscience testing and regulatory studies.
Driving Digital Transformation and Innovation
By designating Scientist.com as its preferred sourcing channel, Bayer Innovation Procurement has created a single digital entry point for its scientists – enabling access to both strategic and niche providers, automating governance, supporting sustainability goals, and generating actionable insights from aggregated procurement data. This transformation is part of Bayer Innovation Procurement’s strategy to empower Bayer researchers and increase the flexibility and productivity of R&D activities in line with the company wide operating model Dynamic Shared Ownership. The full expansion of Crop Science Research and Clinical Development Services are expected to steadily roll out over the next 6-12 months to enable for the onboarding of Bayer’s full provider list.
Leadership Perspectives
“Scientist.com has proven its value right from the beginning, and this extension makes it the one place our scientists go for most of their external work,” said Dr. Kirstin Meyer, SVP and Head of Pre-clinical Development Research, Bayer AG. “With a single entry point we can reach strategic and niche providers alike, ensure governance, drive our sustainability goals and – critically – generate insights from the aggregated data to guide future decisions.”
“Bayer is showing how a digital procurement orchestration platform can serve as an enterprise solution that streamlines an entire research organization's sourcing processes," said Dr. Dan Kagan, President & COO, Scientist.com. “Together we’re adding new AI tools, deeper data integrations and end-to-end compliance so Bayer teams across Pharma and Crop Science can innovate faster and smarter.”
Scientist.com’s AI-enabled platform combines supplier discovery, competitive bidding, contracting, compliance checks and spend analytics in one secure environment, giving Bayer researchers a seamless path to the expertise they need while unlocking portfolio-level insights from the underlying data.
A Model for the Future of R&D
The evolution of Bayer’s partnership with Scientist.com exemplifies how leading life science organizations are moving beyond tactical procurement toward strategic, digitally enabled R&D outsourcing. This approach not only enhances operational efficiency but also positions Bayer to better leverage global expertise, accelerate innovation, and respond to changing scientific and market demands.
About Scientist.com
Scientist.com is the life-science industry’s premier AI-powered marketplace and procurement-orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. More than 20 of the world’s top 30 pharma companies, 100+ biotech organizations and the US National Institutes of Health rely on Scientist.com to access a vetted network of 6,000+ specialized providers, shorten cycle times and reduce costs while meeting the highest ethical and regulatory standards. Discover how Scientist.com accelerates science at Scientist.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250616174530/en/
Contacts
Scientist.com
Sean Preci
+1 877-644-3044
marketing@scientist.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlightSafety International Receives FAA Approval for Virtual Aircraft Preflight Inspection with Evaluation Mode6.5.2026 17:05:00 EEST | Press release
FlightSafety International Inc., the global leader in aviation training and simulation technology, today announced it has received Federal Aviation Administration (FAA) approval for Virtual Aircraft Preflight Inspection (VAPI) with Evaluation Mode for three aircraft training programs: the Embraer EMB-550, Gulfstream G500/G600, and Citation Latitude. This innovative capability allows pilots in initial training to complete a 3D virtual aircraft preflight inspection while in Training Mode, with the added ability to transition directly into the flight deck, followed by Evaluation Mode, that allows pilots to do their preflight check ride portion. “VAPI represents a meaningful advancement in training innovation,” said David Penney, VP of Safety, Courseware and Regulatory Affairs, FlightSafety International. “By leveraging an immersive 3D environment, it offers pilots a more engaging and practical way to develop aircraft familiarity, strengthen inspection discipline, and better prepare for re
Riskified Unveils Next-Generation AI Suite at Ascend 2026, Empowering Merchants with Unprecedented Visibility and Control Over Ecommerce Risk6.5.2026 16:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced a major leap forward in its AI platform capabilities, introducing a powerful suite of control and empowerment tools designed to give merchant fraud teams complete visibility into risk patterns and identity behavior, conversational AI-driven insights, and the ability to surgically tailor their risk strategies. The innovation suite was announced onstage at Ascend 2026, Riskified’s premier global summit series, taking place May 4-6, 2026, at the Conrad New York Downtown in Manhattan, NY. With global ecommerce continuing to expand and losses from AI-driven fraud attacks projected to spike, particularly with the rise of agentic commerce, where AI bots may conduct transactions on behalf of consumers, accurate fraud decisions are fundamental, but are no longer enough. Today, more than ever, sophisticated fraud and risk teams need to understand the why behind every transaction and pattern, and req
Twilio’s Next Generation Platform: An Infrastructure Layer for Every Conversation in the Agentic Era6.5.2026 16:00:00 EEST | Press release
Twilio (NYSE: TWLO), the infrastructure for customer engagement in the AI era, kicked off its user conference, SIGNAL, by unveiling its next generation platform capabilities for the agentic era. Generally available today, Conversation Memory, Conversation Orchestrator, Conversation Intelligence, and Agent Connect combine to turn disparate interactions into continuous, intelligent, and personal conversations across humans, agents, and systems. “The agentic era is here. Agents are joining conversations alongside the people they represent, and modern customer engagement requires an infrastructure that serves both equally,” said Khozema Shipchandler, Chief Executive Officer at Twilio. “Twilio’s new platform is the foundational infrastructure layer that makes every conversation persistent, contextual, and actionable – ensuring interactions feel like part of one continuous relationship." An Infrastructure Layer for Every Conversation Every business runs on conversations. Today, however, busi
Vultr, SUSE & Supermicro Debut Unified Cloud-to-Edge Architecture for Global AI Scaling6.5.2026 15:00:00 EEST | Press release
Vultr, the world's largest privately-held cloud infrastructure company, in collaboration with SUSE and Supermicro, today announces a strategic architectural framework designed to solve the complexities of deploying and operating AI workloads across distributed environments. As AI moves closer to the point of data creation - from manufacturing floors to retail storefronts - organizations face significant challenges in latency, cost and operational consistency. This joint initiative provides a seamless, Cloud-to-Edge pipeline that integrates high-performance hardware, localized cloud infrastructure, and unified Kubernetes management. The partnership addresses the reality that sending all data back to a central cloud is no longer viable for real-time AI. The solution breaks down the infrastructure into three critical layers: The Cloud and Near-Edge - Enterprises can deploy regional Kubernetes-based AI clusters closer to their users by leveraging Vultr’s 33 global cloud data center regions
Waiv Enters Collaboration with Daiichi Sankyo to Deliver AI-Derived Biomarkers for ADC Program6.5.2026 15:00:00 EEST | Press release
Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo (TSE: 4568) to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program. With deep expertise across diverse pathology and multimodal data, and a global data network spanning academic institutions, hospitals, and laboratories, Waiv has a proven track record delivering AI-powered biomarker solutions across the full drug development lifecycle. Under the collaboration, Waiv will apply its end-to-end computational pathology platform to early phase data. This includes tumor microenvironment (TME) analysis across both hematoxylin and eosin (H&E) and immunohistochemistry (IHC) stained samples, as well as biomarker discovery and outcome prediction capabilities aimed at identifying biomarkers of treatment response ahead of next clinical trial phases. Purpose-built AI approach tackles one of pharma's hardest challenges: b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom